2025
Gambling disorder and problematic pornography use: Does co-occurrence influence treatment outcome?
Mestre-Bach G, Potenza M, Granero R, Håkansson A, Gómez-Peña M, Perales I, Vicó À, Uríszar J, Fernández-Aranda F, Sánchez I, Jiménez-Murcia S. Gambling disorder and problematic pornography use: Does co-occurrence influence treatment outcome? Journal Of Behavioral Addictions 2025, 14: 465-479. PMID: 40116860, DOI: 10.1556/2006.2025.00023.Peer-Reviewed Original ResearchConceptsCognitive-behavioral therapyGambling disorderPornography useEmotion regulationGD severityTreatment outcomesCognitive-behavioral therapy approachCognitive-behavioral therapy sessionsTreatment outcomes of individualsCo-occurrence of GDCo-occurrenceMental health concernsImprove treatment adherenceBehavioral addictionsTreatment dropoutOutcomes of individualsWeekly sessionsTreatment adherencePsychopathologyGamblingSessionsDisordersAssociated with higher likelihoodRelapseImpulseChimerism testing in myeloid malignancies: techniques, considerations, and connections to post-transplant outcomes
Puzo C, Siddon A. Chimerism testing in myeloid malignancies: techniques, considerations, and connections to post-transplant outcomes. Pathology 2025, 57: 267-275. PMID: 39934013, DOI: 10.1016/j.pathol.2024.12.632.Peer-Reviewed Original ResearchLineage specific chimerismChimerism testingMyeloid malignanciesCell burdenHematopoietic cellsPost allogeneic stem cell transplantationHost hematopoietic cellsMalignant cell burdenLeukemic cell burdenStem cell transplantationRisk of relapseRecipient hematopoietic cellsPost-transplant outcomesCell transplantationRelapse detectionRecipient chimerismTherapy decisionsRelapsePercentage of donorsChimerismHigh riskConcurrent useChimerism percentageEarly identificationMalignancy
2024
Trigeminal neuralgia within the disease course of MS: Diagnostic and therapeutic implications from a multicenter cohort.
Laakso S, Oh J, Raufdeen F, Jones A, Reiskanen H, Feb K, Levit E, Solomon A. Trigeminal neuralgia within the disease course of MS: Diagnostic and therapeutic implications from a multicenter cohort. Multiple Sclerosis Journal 2024, 13524585241309257. PMID: 39727322, DOI: 10.1177/13524585241309257.Peer-Reviewed Original ResearchTrigeminal neuralgiaClinical relapseMultiple sclerosisActive diseaseEvidence of active diseaseDisease course of MSAssociated with multiple sclerosisCourse of MSDemyelination symptomsMulticenter cohortDisease courseTherapeutic decisionsTherapeutic implicationsMS diagnosisNeuralgiaRelapseDiseaseOnsetSclerosisUltra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction
Li X, Liu T, Bacchiocchi A, Li M, Cheng W, Wittkop T, Mendez F, Wang Y, Tang P, Yao Q, Bosenberg M, Sznol M, Yan Q, Faham M, Weng L, Halaban R, Jin H, Hu Z. Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction. EMBO Molecular Medicine 2024, 16: 2188-2209. PMID: 39164471, PMCID: PMC11393307, DOI: 10.1038/s44321-024-00115-0.Peer-Reviewed Original ResearchMolecular residual diseaseCirculating tumor DNAWhole-genome sequencingCell-free DNAGenome sequenceDetection of molecular residual diseaseCirculating tumor DNA detectionResidual disease detectionConsistent with clinical outcomesVariant allele frequencyResidual diseaseMelanoma patientsMonitoring immunotherapyTumor DNAEsophageal cancerClinical outcomesColorectal cancerWGS technologiesAllele frequenciesCancerDNAAnalytical sensitivitySequenceImmunotherapyRelapseStress and substance use disorders: risk, relapse, and treatment outcomes
Sinha R. Stress and substance use disorders: risk, relapse, and treatment outcomes. Journal Of Clinical Investigation 2024, 134: e172883. PMID: 39145454, PMCID: PMC11324296, DOI: 10.1172/jci172883.Peer-Reviewed Original ResearchConceptsSubstance use disordersDrug-related environmentPathophysiology of addictionAdaptive stress responseSUD treatment outcomesAssociated with substance misuseTreatment outcomesStress-related alterationsDrug motivationIncreased cravingNeurobiological disruptionsMaladaptive copingRepeated stressorsTreatment implicationsSubstance misuseStress pathophysiologyStress responseDrug intakeDrug withdrawalRelapse riskDrug misuseIntervention developmentDisordersCravingRelapseBuprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial
Balter D, Puglisi L, Dziura J, Fiellin D, Howell B. Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial. Journal Of Substance Use And Addiction Treatment 2024, 164: 209438. PMID: 38857827, PMCID: PMC11300157, DOI: 10.1016/j.josat.2024.209438.Peer-Reviewed Original ResearchXR-NTXBuprenorphine-naloxoneOpioid use disorderCriminal legal involvementUse disorderHazard of overdoseLifetime incarcerationLegal involvementOpioid use disorder treatment outcomesPer-protocol analysisExtended-release naltrexoneMOUD effectivenessTreatment outcomesEffects of medicationHazard of relapseSecondary analysisIntention-to-treat analysisIntention-to-treatRandomized controlled trialsEffects of MOUDRelapseControlled trialsDisordersOpioidPotential effect modifiersNormal Erythroid Precursors in Diamond-Blackfan Anemia: A Rare Case Highlighting Challenges That Remain
Prior D, Sowa A, Pashankar F. Normal Erythroid Precursors in Diamond-Blackfan Anemia: A Rare Case Highlighting Challenges That Remain. Journal Of Pediatric Hematology/Oncology 2024, 46: e195-e198. PMID: 38277626, DOI: 10.1097/mph.0000000000002820.Peer-Reviewed Original ResearchConceptsDiamond-Blackfan anemiaDiamond-BlackfanDiagnosis of Diamond-Blackfan anemiaInherited bone marrow failure syndromeBone marrow failure syndromesMarrow failure syndromesDiagnostically challenging casesFailure syndromeAtypical manifestationsSpontaneous remissionRare caseErythroid precursorsChallenging casesGenetic etiologyPhenotypic manifestationsAnemiaPatientsRemissionRelapseHypoplasiaSyndromeEtiologyDiagnosis
2023
Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments
Krystal J, Kaye A, Jefferson S, Girgenti M, Wilkinson S, Sanacora G, Esterlis I. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2305772120. PMID: 38011560, PMCID: PMC10710048, DOI: 10.1073/pnas.2305772120.Peer-Reviewed Original ResearchMOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity
Yandamuri S, Filipek B, Obaid A, Lele N, Thurman J, Makhani N, Nowak R, Guo Y, Lucchinetti C, Flanagan E, Longbrake E, O’Connor K. MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity. JCI Insight 2023, 8: e165373. PMID: 37097758, PMCID: PMC10393237, DOI: 10.1172/jci.insight.165373.Peer-Reviewed Original ResearchConceptsMyelin oligodendrocyte glycoprotein antibody-associated diseaseAntibody-dependent cellular phagocytosisAntibody-dependent cellular cytotoxicityComplement-dependent cytotoxicityMOG autoantibodiesPatient seraCellular cytotoxicityEffector functionsComplement activityAntibody-associated diseaseMultiple mechanismsNK cellsPatient autoantibodiesCytotoxic capacityLesion histologyCellular phagocytosisFuture relapseIgG subclassesCerebrospinal fluidAutoantibodiesCNS conditionsMOGSerumRelapseCytotoxicityPredictors and Etiologies of Clinical Relapse Among Patients With Ulcerative Colitis in Deep Remission
Zeina T, Gandhi S, Mittal A, Levy A, Weinstock J, Singh S, Jangi S. Predictors and Etiologies of Clinical Relapse Among Patients With Ulcerative Colitis in Deep Remission. Journal Of Clinical Gastroenterology 2023, 58: 195-199. PMID: 36753459, PMCID: PMC10406966, DOI: 10.1097/mcg.0000000000001834.Peer-Reviewed Original ResearchConceptsEtiology of relapseRisk of relapseCumulative risk of relapseRisk of clinical relapseDeep remissionDiscontinuation of therapyClinical relapseUlcerative colitisNormalization of C-reactive proteinCumulative riskRetrospective cohort studyC-reactive proteinTufts Medical CenterEndoscopic remissionHistological remissionRelapse riskIdentified etiologyRemissionRelapseCohort studyPatientsHistological changesMedical recordsColitisElectronic medical recordsAn overview of novel therapies in advanced clinical testing for acute myeloid leukemia
Venugopal S, Xie Z, Zeidan A. An overview of novel therapies in advanced clinical testing for acute myeloid leukemia. Expert Review Of Hematology 2023, 16: 109-119. PMID: 36718500, DOI: 10.1080/17474086.2023.2174521.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAML therapyMolecular pathogenesisApproval of midostaurinPathophysiology of AMLMeasurable residual diseaseAdvanced clinical testingClinical trial developmentAcute myeloid leukemiaCell surface antigensDevelopment of agentsDisease relapseImmune environmentAML treatmentResidual diseaseTherapeutic armamentariumMyeloid leukemiaNovel therapiesSurface antigenClinical testingTrial developmentTherapyAMLEscape mechanismsGene mutationsRelapse
2022
Streamline - Retrospective Cohort Study of FLT3-mutated Acute Myeloid Leukemia (AML): Real-World Treatment Patterns and Clinical Outcomes after First Relapse or Refractory (R/R) Diagnosis
Zeidan A, Gautam S, Yu R, Lan Z, Grinblatt D, ElSouda D, Spalding J, Block A, Touya M, Pandya B. Streamline - Retrospective Cohort Study of FLT3-mutated Acute Myeloid Leukemia (AML): Real-World Treatment Patterns and Clinical Outcomes after First Relapse or Refractory (R/R) Diagnosis. Blood 2022, 140: 8124-8126. DOI: 10.1182/blood-2022-166692.Peer-Reviewed Original ResearchClinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Badar T, Atallah E, Saliba A, Shallis R, Stahl M, Bewersdorf J, De Camargo Correia G, Patel A, Abaza Y, Murthy S, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kota V, Dinner S, Goldberg A, Litzow M. Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood 2022, 140: 6058-6060. DOI: 10.1182/blood-2022-163795.Peer-Reviewed Original ResearchReemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy
Fichtner ML, Hoehn KB, Ford EE, Mane-Damas M, Oh S, Waters P, Payne AS, Smith ML, Watson CT, Losen M, Martinez-Martinez P, Nowak RJ, Kleinstein SH, O’Connor K. Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy. Acta Neuropathologica Communications 2022, 10: 154. PMID: 36307868, PMCID: PMC9617453, DOI: 10.1186/s40478-022-01454-0.Peer-Reviewed Original ResearchConceptsB cell depletion therapyB cell clonesMuSK-MG patientsMyasthenia gravisB cellsMG patientsDepletion therapyCell clonesAutoantibody-producing B cellsMuscle-specific tyrosine kinaseComplete stable remissionB cell receptor repertoireCell receptor repertoireValuable candidate biomarkersB cell receptorMG relapseClinical relapseStable remissionDisease relapseAutoimmune disordersRelapsePatientsAcetylcholine receptorsCandidate biomarkersReceptor repertoireNon-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Pacheco JM, Patel SP, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 497-530. PMID: 35545176, DOI: 10.6004/jnccn.2022.0025.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNCCN Clinical Practice GuidelinesCell lung cancerClinical practice guidelinesLung cancerPractice guidelinesMetastatic non-small cell lung cancerMetastatic lung cancerNCCN guidelinesPrimary treatmentTargeted therapyActionable mutationsPatientsCancerSubsequent treatmentTherapyOncologyTreatmentGuidelinesImmunotherapyRelapseDiagnosisRates of idiopathic childhood nephrotic syndrome relapse are lower during the COVID-19 pandemic
Crane C, Bakhoum C, Ingulli E. Rates of idiopathic childhood nephrotic syndrome relapse are lower during the COVID-19 pandemic. Pediatric Nephrology 2022, 37: 2679-2685. PMID: 35211788, PMCID: PMC8869345, DOI: 10.1007/s00467-022-05483-8.Peer-Reviewed Original ResearchConceptsSteroid-sensitive nephrotic syndromeRate of relapseNephrotic syndromeTransmission of infectionNS relapseGraphical abstractA higher resolution versionSingle-center retrospective chart reviewNephrotic syndrome relapseSteroid-sensitive NSRetrospective chart reviewLower relapse rateRate of hospitalizationInfection prevention measuresResultsOne hundred twentyCOVID-19 pandemicPre-pandemic periodChart reviewRelapse rateInfection preventionHundred twentyRelapseStudy periodSocial distancing periodConclusionsOur resultsDecreased rateClinical Management of Opioid Withdrawal
Torres‐Lockhart K, Lu TY, Weimer MB, Stein MR, Cunningham CO. Clinical Management of Opioid Withdrawal. Addiction 2022, 117: 2540-2550. PMID: 35112746, DOI: 10.1111/add.15818.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsOpioid use disorderOpioid withdrawal managementOpioid withdrawalClinical managementWithdrawal managementLong-term treatmentAppropriate clinical managementPatient-centered approachRelapse prevention strategiesHarm reduction strategiesHigh-risk timeOUD treatmentAppropriate diagnosisOpioid overdoseUse disordersPrevention strategiesTreatment settingsNarrative reviewWithdrawalTreatmentComplex casesManagementRelapsePatientsOverdose
2020
Nocardia veterana infections: case report and systematic review
Radcliffe C, Peaper D, Grant M. Nocardia veterana infections: case report and systematic review. New Microbes And New Infections 2020, 39: 100833. PMID: 33456780, PMCID: PMC7797559, DOI: 10.1016/j.nmni.2020.100833.Peer-Reviewed Case Reports and Technical NotesChronic cutaneous graftOral antibiotic therapySoft tissue abscessesHost diseaseCutaneous graftAntibiotic therapyPulmonary infectionCase reportDrainage proceduresEmpirical treatmentCondition warrantsSystematic reviewInfectionOpportunistic pathogenSystematic literature reviewFirst reportLiterature reviewReportAbscessRelapseReviewAzithromycinGraftTherapyNocardiaPatterns of Transitions Between Relapse to and Remission From Heavy Drinking Over the First Year After Outpatient Alcohol Treatment and Their Relation to Long-Term Outcomes
Maisto SA, Hallgren KA, Roos CR, Swan JE, Witkiewitz K. Patterns of Transitions Between Relapse to and Remission From Heavy Drinking Over the First Year After Outpatient Alcohol Treatment and Their Relation to Long-Term Outcomes. Journal Of Consulting And Clinical Psychology 2020, 88: 1119-1132. PMID: 33370135, PMCID: PMC7900838, DOI: 10.1037/ccp0000615.Peer-Reviewed Original ResearchConceptsLong-term outcomesHeavy drinkingBetter long-term outcomesAlcohol use disorder treatmentRemission/relapsePattern of remissionOutpatient alcohol treatmentUse disorder treatmentFirst yearContinuous relapseContinuous remissionMore relapsesClinical courseOutpatient treatmentRemissionDrinking statusLong-term recoveryRelapsePosttreatment periodDisorder treatmentAlcohol treatmentRelapse episodesAverage durationFunctioning outcomesHeavy drinking statusBrachial plexus chloroma as a presenting feature of relapse in a child with KMT2A-rearranged acute lymphoblastic leukemia, a case report
Pruitt J, Flagg A, Hanna R, Rotz SJ. Brachial plexus chloroma as a presenting feature of relapse in a child with KMT2A-rearranged acute lymphoblastic leukemia, a case report. Pediatric Hematology And Oncology 2020, 38: 179-183. PMID: 33150840, PMCID: PMC7987733, DOI: 10.1080/08880018.2020.1826071.Peer-Reviewed Case Reports and Technical Notes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply